OIS@ASRS
Vitrectomy technology has changed little since Robert Machemer, MD, invented his 17-gauge single-port pneumatic cutter in 1972, Bausch + Lomb senior VP and chief medical…
Read More
In the large world of private funding in health care, ophthalmology pales in comparison with huge sectors like oncology and cardiovascular, but ophthalmology has had…
Read More
US financial markets had “the worst 10-day start for Wall Street in history” in January 2016, said Andrew Gitkin, managing director and head of West…
Read More
The lead-up to OIS@ASRS had been eventful for biotech company PFEnex, as Hubert C. Chin, MD, chief medical officer, reported to the “Paying for Breakthrough…
Read More
AGTC is pursuing six different genetic treatments for four different retinal diseases, and expects to have clinical data from its Phase I trial of its…
Read More
Regeneron Pharmaceuticals Inc. markets the highly successful anti-VEGF injection EYLEA (aflibercept), which is FDA approved for neovascular (wet) age-related macular degeneration (AMD), macular edema following…
Read More
Aerpio Therapeutics is focused on the development of novel therapeutics for vascular disorders, with a concentration on eye diseases. Joseph Gardner, CEO of Aerpio, provided…
Read More
Allegro Ophthalmics is developing Luminate, a first-in-class anti-integrin peptide with a novel mechanism of action for both anti-angiogenesis and vitreolysis. The company is in late-stage…
Read More
Opthea, a public company listed on the Australian Stock Exchange, is developing OPT-302, a novel therapy for wet age-related macular degeneration (AMD). The company’s lead…
Read More
Contributed By: Michael Lachman The OIS@ASRS panel discussion on Emerging Approaches to Combination Therapies in AMD & DME was moderated by Mark Humayan, MD, PhD,…
Read More
William J. Link, PhD, managing director of Versant Ventures, gathered the leaders in imaging to outline what’s ahead for retina. Participants were Ralf Kuschnereit, PhD,…
Read More
Retinal disease remains a challenging target for drug and device makers, but a panel of senior executives at last week’s OIS@ASRS says the potential benefits…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")